RT Journal Article
SR Electronic
T1 The EPILOG Trial
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 267
OP 272
VO 65
IS 5
A1 Roe, Matthew T.
A1 Moliterno, David J.
YR 1998
UL http://www.ccjm.org/content/65/5/267.abstract
AB The EPILOG trial showed that the platelet glycoprotein llb/llla inhibitor abciximab, together w i t h heparin in a low, w e i g h t -adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, w i t h o u t increasing the risk of hemorrhage.